Aligos Therapeutics Inc. held its Annual Meeting of Stockholders on June 25, 2025. During the meeting, stockholders approved several proposals. The election of three Class II directors was confirmed. The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. An amendment to the 2020 Plan to increase the number of shares reserved by 1,000,000 shares was approved. Additionally, an amendment to the Company's Amended and Restated Bylaws was approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.